HENRY FORD HEALTH SYSTEM

Second University of Minnesota Study Shows No Hydroxychloroquine Benefit in COVID-19 Fight

4 months ago

A second University of Minnesota study has found that hydroxychloroquine, an anti-malaria drug once championed by President Donald Trump, does not provide substantial benefits in treating COVID-19. The study compared outcomes of patients taking hydroxychloroquine with those taking a placebo and found no significant differences in death rates, hospitalizations, or persistent symptoms. The findings add to the growing evidence against the use of hydroxychloroquine for COVID-19 treatment.

FDA Approves Organon's Vtama (Tapinarof) Cream for Atopic Dermatitis in Adults and Children

5 months ago

• The FDA has approved Vtama (tapinarof) cream 1% for treating atopic dermatitis in adults and children aged 2 years and older. • Vtama demonstrated statistically significant improvements in skin clearance and itch reduction compared to the vehicle in clinical trials. • The treatment offers a steroid-free option with no label warnings, contraindications, or restrictions on treatment duration or body surface area affected. • Long-term studies showed sustained efficacy and a favorable safety profile, with many patients experiencing extended treatment-free intervals.

Lebrikizumab Shows Promise in Atopic Dermatitis Patients Previously Treated with Dupilumab

7 months ago

• Phase 3b ADapt study reveals lebrikizumab significantly improved skin condition and reduced itch in moderate-to-severe atopic dermatitis patients who discontinued dupilumab. • 57% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) at week 16, increasing to 60% by week 24 with lebrikizumab treatment. • A notable 53% of patients experienced a 4-point or greater reduction in pruritus scores at week 16, with improvements observed in challenging areas like the face and hands. • Lebrikizumab demonstrated a safety profile consistent with prior studies, with fewer than 6% of participants discontinuing treatment due to adverse effects.